Bausch Health Cos (NYSE:BHC) Reaches New 52-Week Low – Should You Sell?

Bausch Health Cos Inc. (NYSE:BHC)’s share price hit a new 52-week low during trading on Tuesday . The stock traded as low as $4.35 and last traded at $4.4540, with a volume of 572901 shares trading hands. The stock had previously closed at $4.68.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BHC. Weiss Ratings cut shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 4th. Royal Bank Of Canada lowered their target price on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a report on Monday, April 27th. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Bausch Health Cos currently has a consensus rating of “Reduce” and an average price target of $8.00.

Bausch Health Cos Price Performance

The stock has a 50-day moving average price of $5.07 and a 200 day moving average price of $5.61. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.32 and a quick ratio of 0.97. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -1.40 and a beta of 0.42.

Bausch Health Cos (NYSE:BHC) last announced its earnings results on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.37 billion. Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. As a group, equities research analysts forecast that Bausch Health Cos Inc. will post 4.05 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Bausch Health Cos news, Director Frank D. Lee sold 24,456 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total value of $132,796.08. Following the completion of the sale, the director owned 49,339 shares in the company, valued at approximately $267,910.77. The trade was a 33.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.67% of the company’s stock.

Institutional Trading of Bausch Health Cos

Institutional investors and hedge funds have recently bought and sold shares of the business. Caption Management LLC grew its position in Bausch Health Cos by 101.1% during the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock worth $31,000 after purchasing an additional 405,789 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of Bausch Health Cos by 12,589.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock valued at $34,000 after buying an additional 4,910 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Bausch Health Cos by 6,661.2% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after buying an additional 5,329 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Bausch Health Cos by 65.9% during the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after buying an additional 3,106 shares during the period. Finally, Camelot Portfolios LLC acquired a new stake in shares of Bausch Health Cos during the fourth quarter worth about $59,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.